Table 2. Univariate survival analyses of LC patients according to various clinicopathological variables.
| Variable | n | 5-year LCSS (%) | Log rank χ2 test | p value |
|---|---|---|---|---|
| Years of diagnosis | 454.61 | P < 0.001 | ||
| 1988–1993 | 4505 | 4.3% | ||
| 1994–1999 | 8525 | 7.4% | ||
| 2000–2003 | 14225 | 11.2% | ||
| Sex | 4.69 | P < 0.05 | ||
| Male | 19324 | 8.8% | ||
| Female | 7931 | 9.2% | ||
| Age | 85.22 | P < 0.001 | ||
| ≤ 45 | 2102 | 14.5% | ||
| > 45 | 25153 | 8.4% | ||
| Race | 199.66 | P < 0.001 | ||
| Caucasian | 17891 | 8.5% | ||
| African American | 2998 | 5.7% | ||
| Others* | 6366 | 11.5% | ||
| Primary site | 23.04 | P < 0.001 | ||
| Liver | 24317 | 9.4% | ||
| Intrahepatic bile duct | 2938 | 4.6% | ||
| Pathological grading | 597.76 | P < 0.001 | ||
| High/Moderate | 6548 | 17.8% | ||
| Poor/undifferentiation | 3023 | 7.0% | ||
| Histological Type | 20.99 | P < 0.001 | ||
| Hepatocellular carcinoma | 23547 | 9.5% | ||
| Cholangiocarcinoma | 3502 | 5.1% | ||
| Combined | 206 | 6.8% | ||
| Stage | 3135.26 | P < 0.001 | ||
| Localized | 9100 | 18.5% | ||
| Regional | 7077 | 5.8% | ||
| Distant | 5467 | 1.5% | ||
| Tumor size | 953.15 | P < 0.001 | ||
| < 3cm | 2088 | 31.3% | ||
| 3–5cm | 4155 | 15.7% | ||
| > 5cm | 7618 | 8.2% |
*
including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.